Rapt Therapeutics Stock News

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing a

RAPT Therapeutics, Inc. (NASDAQ:RAPT) insider Dirk G. Brockstedt sold 2,647 shares of the businesss stock in a transaction dated Friday, December 10th. The shares were sold at an average price of $30.88, for a total value of $81,739.36. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. []

JPMorgan Chase & Co. initiated coverage on shares of RAPT Therapeutics (NASDAQ:RAPT) in a research note published on Thursday morning, Price Targets.com reports. The firm issued an overweight rating and a $61.00 target price on the stock. A number of other equities research analysts have also recently commented on the stock. Zacks Investment Research upgraded []

RAPT Therapeutics, Inc. (NASDAQ:RAPT) insider Dirk G. Brockstedt sold 2,648 shares of the stock in a transaction dated Thursday, November 11th. The shares were sold at an average price of $35.69, for a total transaction of $94,507.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at []

JPMorgan Chase & Co. began coverage on shares of RAPT Therapeutics (NASDAQ:RAPT) in a research report report published on Thursday, Analyst Price Targets reports. The brokerage issued an overweight rating and a $61.00 price objective on the stock. Other equities research analysts also recently issued reports about the company. SVB Leerink reaffirmed a buy rating […]

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have received a consensus recommendation of Buy from the seven analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among brokerages that []

Credit Suisse AG cut its holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 10.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,367 shares of the companys stock after selling 1,090 shares during the period. Credit Suisse AGs holdings in RAPT Therapeutics were worth $297,000 []

UBS Asset Management Americas Inc. purchased a new position in RAPT Therapeutics, Inc. (NASDAQ:RAPT) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 7,100 shares of the companys stock, valued at approximately $226,000. A number of other hedge funds []

Nuveen Asset Management LLC grew its holdings in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 28.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 53,957 shares of the companys stock after acquiring an additional 11,866 shares during the period. Nuveen [] The post Nuveen Asset Management LLC Has $1 Million Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT) appeared first on ETF Daily News .

RAPT Therapeutics (NASDAQ:RAPT) had its price objective dropped by analysts at Cantor Fitzgerald from $71.00 to $58.00 in a research report issued to clients and investors on Tuesday, The Fly reports. The firm currently has an overweight rating on the stock. Cantor Fitzgeralds target price suggests a potential upside of 61.83% from the stocks current []

RAPT Therapeutics (NASDAQ:RAPT) had its price target cut by Cantor Fitzgerald from $71.00 to $58.00 in a research report report published on Tuesday, The Fly reports. They currently have an overweight rating on the stock. RAPT has been the subject of a number of other research reports. Zacks Investment Research upgraded RAPT Therapeutics from a []

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Analysts at Piper Sandler dropped their FY2021 earnings per share (EPS) estimates for shares of RAPT Therapeutics in a research note issued to investors on Wednesday, November 10th. Piper Sandler analyst E. Tenthoff now expects that the company will post earnings per share of ($2.58) for the year, down from []

Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of -5.00% and -33.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Rapt Therapeutics (RAPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.